Starpharma Investor Presentation for Citi Conference
Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) will today participate in Citi's 10th Annual Australian and New Zealand Investment Conference in Sydney.
Small Caps publication covers DEP® irinotecan candidate’s positive performance in pancreatic cancer model
|
Small Caps, a specialist investment publication, covered the positive news that Starpharma’s DEP® irinotecan showed complete tumour regression and 100% survival in a human pancreatic cancer model. |
Read the full article here.
DEP® irinotecan outperforms in pancreatic cancer model
Melbourne, Australia: Starpharma today announced that its proprietary DEP® irinotecan development candidate showed significant efficacy and safety benefits over standard irinotecan in combination with 5-FU in a mouse xenograft model of human pancreatic cancer (Figure 1 and 2). The human pancreatic tumour model used in this study virtually did not respond to the traditional irinotecan regimen (irinotecan + 5-FU), whereas complete tumour regression and 100% survival was achieved using Starpharma’s DEP® irinotecan.
AstraZeneca’s DEP Bcl2/xL inhibitors show compelling efficacy and synergy in combination
Melbourne, Australia; Starpharma today announced AstraZeneca’s first patent application on DEP® Bcl2/xL conjugates has been published by the World Intellectual Property Organisation. These DEP® Bcl2/xL conjugates combine Starpharma’s innovative DEP® delivery technology with AstraZeneca’s novel Bcl2/xL inhibitor for treating various cancers, including leukemias.
The published patent application shows compelling efficacy data on DEP® Bcl2/xL conjugates, both alone and in combination with other leading current anti-cancer treatments, in various preclinical human tumour models.
Motley Fool ‘Extreme Opportunities’ Advisor Dr Anirban Mahanti covers Starpharma’s 2018 Financial Year Results
Dr Anirban Mahanti, Advisor at Motley Fool writes that FY18 was a “hugely transformative year for Starpharma”, noting the Company’s key milestones including its “smart licensing agreements” and “potentially game-changing pipeline of drugs”. Originally published on Motley Fool and republished with permission. Read the full article here.
Annual report and full year financial results
Melbourne, Australia: Starpharma today released its annual report and financial results for the year ended 30 June 2018.
Starpharma: To win big in science, industry needs business-friendly scientists
|
The Australian Financial Review covered Starpharma CEO Dr Jackie Fairley’s appearance at the AFR Innovation Summit, noting she highlighted that the biotech sector needs more business-friendly scientists to help hit more ‘home runs’ in medical science. |
Read the full article here (paywall).
Quarterly Cashflow Report
Melbourne, Australia; Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2018.
Starpharma CEO Dr Jackie Fairley interviewed by Alan Kohler for The Constant Investor
VivaGel® BV NDA advances to next stage of FDA review
Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that the US FDA has completed its filing review of the VivaGel® BV New Drug Application (NDA), with no issues identified, and confirmed its progress to the next stage.